Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$9.21 USD
+0.12 (1.26%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $9.22 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 61 - 80 ( 131 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
066 Patent Becomes Key to Unlock Full YUTREPIA Approval;Trial in March 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
First & Goal: Tentative Approval Gained, Patent Trial Outcome To Go in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Secures Tentative Approval..Considerations for Ongoing Litigation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Sights Set on LIQ861 PDUFA for Tentative Approval on Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
''901 Ruling and Tyvaso DPI CRL Give Boost to LIQ861 as PDUFA Approaches
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Extended Cash Runway, LIQ861 PDUFA for Tentativ Approval on Nov. 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Subcutaneous Generic Treprostinil Makes Its Appearance; LIQ861 Advancement in PAH
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
LIQ861/PAH PDUFA for Tentative Approval Set for November 7, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
LIQ861 Focus With NDA Resubmission; Backdrop of Generic Treprostinil Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Cash Runway Covers Key Milestones; LIQ861/ PAH NDA Resubmitted
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Generic Treprostinil Injection/PAH to be Available via SC Route
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY20: Streamlining Operations in 2021; Focus on Path Forward for LIQ861
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L